Sun Pharmaceutical Industries informs about company updates

02 Dec 2019 Evaluate

Sun Pharmaceutical Industries has informed that the Company along with its wholly owned subsidiaries (together ‘Sun Pharma’) is a defendant in a multi-district litigation brought by various classes of plaintiffs, in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs (Valganciclovir, Valsartan and Esomeprazole). The complaints assert claims under the Racketeer Influenced and Corrupt Organizations Act, federal and state antitrust laws, and state consumer protection laws. These litigations have already been disclosed in the Company’s 2018-19 annual report. On November 27, 2019, the US District Court (District of Massachusetts) entered a decision denying in part and granting in part Sun Pharma’s motion to dismiss the claims of certain plaintiffs. Under the ruling the majority of those plaintiff’s claims survive and several state law claims are dismissed. The litigation is proceeding in discovery. Sun Pharma will continue to vigorously defend against all claims and is also considering its appeal options as to the claims that were not dismissed in the above court decision. 

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Inds. Share Price

1786.05 -40.05 (-2.19%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.